LncRNA H19 contributes to hippocampal glial cell activation via JAK/STAT signaling in a rat model of temporal lobe epilepsy
- 305 Downloads
Astrocyte and microglia activation are well-known features of temporal lobe epilepsy that may contribute to epileptogenesis. However, the mechanisms underlying glia activation are not well understood. Long non-coding RNA (lncRNA) H19 has diverse functions depending on physiological or pathological state, and its role in epilepsy is unknown. We previously demonstrated that H19 was significantly upregulated in the latent period of epilepsy and may be associated with cell proliferation and immune and inflammatory responses. We therefore speculated that H19 is involved in the hippocampal glial cell activation during epileptogenesis.
H19 was overexpressed or knocked down using an adeno-associated viral vector delivery system. A rat status epilepticus model was induced by intra-amygdala kainic acid injection. Astrocyte and microglia activation were assessed by immunofluorescence and western blot analyses. Expression of proinflammatory cytokines and components of the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling pathways were evaluated with western blotting.
H19 overexpression induced the activation of astrocytes and microglia and the release of proinflammatory cytokines (interleukin-1β and interleukin-6 and tumor necrosis factor-α) in the hippocampus, whereas H19 knockdown inhibited status epilepticus-induced glial cell activation. Moreover, H19 activated JAK/STAT signaling by promoting the expression of Stat3 and c-Myc, which is thought to be involved in astrocyte activation.
LncRNA H19 contributes to hippocampal glial cell activation via modulation of the JAK/STAT pathway and could be a therapeutic tool to prevent the development of epilepsy.
KeywordsTemporal lobe epilepsy lncRNA H19 Astrocytes Microglia Inflammatory response
Central nervous system
Glyceraldehyde 3-phosphate dehydrogenase
Glial fibrillary acidic protein
Long non-coding RNA
Nuclear respiratory factor
Short hairpin RNA
Signal transducer and activator of transcription
Temporal lobe epilepsy
Tumor necrosis factor
Temporal lobe epilepsy (TLE) is one of the most common types of intractable epilepsy and is characterized by the periodic and unpredictable occurrence of seizures. Glial cell activation and proliferation, a well-described pathological feature of TLE, can alter blood-brain barrier integrity and ion and neurotransmitter homeostasis and cause an inflammatory response, resulting in neuronal hyperexcitability and the generation and spread of seizure activity [1, 2, 3]. Although impairment of these functions is thought to be associated with the pathophysiology of epilepsy, the mechanisms underlying glial cell activation are complex and are not fully understood .
Long non-coding RNA (lncRNA) H19, an imprinted gene, is located on human chromosome 11 and is transcribed from the maternally inherited allele . Despite being identified over 20 years ago, the function of H19 remains unclear and its pathological role as a non-coding RNA has only recently been elucidated . H19 has diverse functions depending on physiological and pathological state. In the central nervous system (CNS), H19 is overexpressed in glioblastoma tissue and promotes the proliferation, differentiation, migration, and invasion of glioma cells [6, 7]. However, the biological function of H19 in non-neoplastic CNS diseases including epilepsy remains unknown.
We previously showed by high-throughput microarray and bioinformatics analyses that H19 is upregulated in the latent period of TLE in rat and is involved in various aspects of epileptogenesis, including cell proliferation and immune and inflammatory responses . We therefore speculated that H19 may be involved in hippocampal glial cell activation during epileptogenesis. This was investigated in the present study by gain- and loss-of-function studies in a rat model of TLE. We also examined the possible downstream targets of H19.
Animal and human samples
Male Sprague–Dawley rats weighing 200–220 g were obtained from Vital River Experimental Animal Technology Co. (Beijing, China) and were housed in a temperature-controlled room with free access to standard food and water under a 12:12-h light/dark cycle. Surgically resected hippocampus specimens were obtained from patients with intractable TLE who underwent surgical treatment at Beijing Tiantan Hospital. Control hippocampal tissue was obtained from autopsies of four patients without a history of epilepsy or other neurological diseases within 8 h after death.
H19 overexpression and knockdown
H19 was overexpressed or silencing using an adeno-associated viral (AAV) vector delivery system as previously described . Briefly, a vector harboring H19 (AAV-H19) or a short hairpin RNA targeting H19 (AAV-shRNA) was constructed by Gene Chem Co. (Shanghai, China). The negative control was an empty AAV vector (AAV-NC) or one harboring a scrambled sequence (AAV-Scr: 5′-TTCTCCGAACGTGTCACGT-3′). The titers used were 1.0 × 1012 for AAV9-H19 and 4.0 × 1012 for AAV9-shRNA. A total of 6 μl AAV was infused into the right dorsal hippocampus (3.12 mm posterior to the bregma, 3.0 mm lateral to the midline, and 3.4 mm ventral to the bregma) and ventral hippocampus (5.04 mm posterior to the bregma, 5.0 mm lateral to the midline, and 6.4 mm ventral to the bregma; 3 μl at each location)  through a microsyringe at a speed of 0.2 μl/min.
A kainic acid (KA)-induced status epilepticus (SE) model was established by intra-amygdala microinjection of KA 14 days after AAV injection according to our previously described technique . Briefly, the rats were placed in a stereotaxic apparatus (David Kopf Instruments, Tujunga, CA, USA), and 0.7 μl KA (1 μg/μl; Sigma–Aldrich, St. Louis, MO, USA) was injected into the right amygdala (2.76 mm posterior to the bregma, 4.5 mm lateral to the midline, and 8.6 mm ventral to the bregma)  at a speed of 0.2 μl/min. Sham-operated controls were injected with an equal volume of saline.
Coronal sections (25 μm) were prepared at the level of the dorsal hippocampus (2.50–3.50 mm posterior to the bregma). Frozen sections were dried, washed, permeabilized, blocked in 5% goat serum, and incubated overnight with antibodies against neuronal nuclei (NeuN) (ab177487, 1:500 and ab104224, 1:200), glial fibrillary acidic protein (GFAP) (ab7260, 1:500), and OX42 (ab1211, 1:100) (all from Abcam, Cambridge, MA, USA). Immunolabeled sections were washed and incubated with goat secondary antibodies conjugated with Alexa Fluor 594 or Alexa Fluor 488 (Merck Biosciences, Nottingham, UK). Sections were mounted with medium containing 4′,6-diamidino-2-phenylin-dole (DAPI) (Vector Laboratories, Burlingame, CA, USA), and images were captured using an inverted fluorescence microscope (Olympus, Tokyo, Japan). GFAP+ or OX42+ cells were manually counted using ImageJ software (US National Institutes of Health, Bethesda, MD, USA).
Western blot analysis was performed as previously described  using the following primary antibodies: rabbit polyclonal anti-GFAP (ab7260, 1:1000), mouse monoclonal anti-OX42 (ab1211, 1:500), rabbit polyclonal anti-interleukin (IL)-1β (ab9722; 1:500), mouse monoclonal anti-IL-6 (ab9324; 1:500), rabbit polyclonal anti-tumor necrosis factor (TNF)-α (ab6671; 1:500), rabbit monoclonal anti-p-Stat3 (ab76315; 1:500), and rabbit polyclonal anti-c-Myc (ab39688; 1:500) (all from Abcam, Cambridge, MA, USA). Rabbit monoclonal anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibody (Abcam, ab181602, 1:3000) was used as a control. Protein band density was quantified using an Epson V330 Photo scanner (Seiko Epson Co., Nagano, Japan) and Quantity One software (Bio-Rad, Hercules, CA, USA).
Data are presented as mean ± standard error of the mean. Two-group comparisons were made with the unpaired Student’s t test, and multi-group comparisons were made by one-way analysis of variance followed by Sidak’s multiple comparison tests using Prism 5 software (GraphPad Inc., San Diego, CA, USA). Significance was accepted at P < 0.05.
Astrocytes and microglia are activated in the hippocampus of epileptic rats
H19 is involved in the activation of astrocytes and microglia in the hippocampus of epileptic rats
H19 induces astrocyte and microglia activation via JAK/STAT signaling
Most previous studies on H19 function focused on tumorigenesis. H19 was initially proposed as a tumor suppressor due to its capacity to suppress clonogenicity and tumorigenicity in tumor cells [14, 15]. However, recent studies showed that H19 acts as an oncogene by promoting cell proliferation, migration, invasion, and metastasis in various malignancies including glioblastoma [16, 17, 18]. Apart from these functions, H19 is also implicated in several other physiological conditions or diseases, such as cartilage degeneration in osteoarthritis , skeletal muscle differentiation and regeneration , and glucose metabolism in muscle cells . However, the role of H19 in non-neoplastic CNS diseases including epilepsy remains unclear. In the present study, we provide the first evidence that H19 promotes glial cell activation and stimulates inflammation in the hippocampus of rats with TLE.
Astrocyte activation is a continuum that includes changes in molecular expression, progressive cellular hypertrophy, and, in severe cases, proliferation and scar formation . In mild or moderate astrocyte activation, GFAP expression is slightly upregulated and the cell body and processes undergo hypertrophy, with little or no astrocyte proliferation. However, in severe diffuse reactive astrogliosis, GFAP expression is markedly increased, which is accompanied by extensive hypertrophy of the cell body and processes and astrocyte proliferation . In the present study, astrocytes in the hippocampus of epileptic rats were activated in the latent and chronic phases of TLE, which is consistent with previous reports [13, 24]. Mild to moderate gliosis, which typically does not cause astrocyte proliferation, is usually observed in the early stages after SE . We also found that astrocyte activation was mild or moderate, as evidenced by the upregulation of GFAP expression and cellular hypertrophy without an obvious increase in cell number in the latent period of TLE (7 days after SE). Furthermore, H19 induced an increase in GFAP expression and hypertrophy of astrocytes rather than cell proliferation in the latent period of SE. In the chronic period (30 days after SE), astrocyte activation was extreme with severe hypertrophy of the cell body and processes; moreover, astrocyte proliferation in areas of pyramidal neuron loss was comparable to the hippocampal sclerosis observed in TLE patients . Unlike astrocytes, high expression of OX42 protein and cellular hypertrophy as well as proliferation of microglia was observed in both the latent and chronic periods of TLE, as previously reported . Furthermore, H19 induced the upregulation of OX42 and cellular hypertrophy and increased the number of microglia in the latent period of SE. Recent studies have shown that inflammatory cytokines are produced both by microglia and astrocytes ; the increased levels of proinflammatory cytokines in epileptic rats observed here is in agreement with these findings. Moreover, H19 stimulated the release of proinflammatory cytokines. However, compared to sham rats, H19 knockdown did not inhibit proinflammatory cytokine expression, possibly because under normal conditions, proinflammatory cytokine levels in the hippocampus are too low to result in an observable difference upon H19 knockdown.
Molecular triggers that lead to glial cell activation and proliferation have not been fully characterized. There is increasing evidence to suggest that H19 has a growth-promoting function, since it enhances cell proliferation in tumors [29, 30] and other diseases [20, 31]. In the present study, we showed that H19 promotes astrocyte and microglia activation and proliferation under both epileptic and normal conditions. This is consistent with earlier reports as well as with our previous research . Various intracellular signaling pathways associated with Stat3, nuclear factor κB, and nuclear respiratory factor (Nrf) mediate cell hypertrophy, proliferation, and pro- or anti-inflammatory effects in astrocytes . The transcription factor Stat3, a key component of the JAK/STAT pathway, is important for astrocyte proliferation in CNS diseases [11, 32, 33]. P-Stat3 is highly expressed in the rat hippocampus during different phases of epilepsy and in the temporal lobe of TLE patients . Astrocyte activation can be suppressed by inhibiting JAK/STAT signaling, indicating that Stat3 activation induces GFAP expression . In our study, Stat3 as well as its downstream effector c-Myc in the JAK/STAT pathway were upregulated after SE in the rat hippocampus and in TLE patients. Furthermore, H19 overexpression induced whereas its knockdown inhibited Stat3 and c-Myc protein expression in both normal and epileptic rats. Thus, H19 can itself promote gliosis via JAK/STAT signaling in addition to its role in astrocyte activation.
In summary, lncRNA H19 contributes to the activation of hippocampal astrocytes and microglia, as well as to the inflammatory response in epileptic rats. Furthermore, H19 may promote glial cell activation through the JAK/STAT pathway. Our findings reveal a novel lncRNA H19-mediated mechanism in seizure-induced glial cell activation and provide a basis for developing lncRNA-based strategies to prevent the development of epilepsy.
This study was supported by the National Natural Science Foundation of China (81471315).
Availability of data and materials
All data are provided in the manuscript and in the additional files.
CLH performed the experiments and drafted the manuscript. MG analyzed the data. YPL and XMZ established the epilepsy model. KLW performed the intro-hippocampus AAV vector injection. NC performed the immunofluorescence image analysis. WH contributed to the experimental design. WJM performed the animal experiment of AG 490. JGZ assisted with the experiment design and collected the hippocampal samples from patients with TLE. LL designed the study and revised the manuscript. FGM designed and guided the experiment. All authors have read and approved the final version of the manuscript.
Ethics approval and consent to participate
All experimental protocols involving animals were in compliance with the Chinese Animal Welfare Act and Beijing Guidelines for the Care and Use of Laboratory Animals. Written informed consent was obtained from each patient for the use of brain tissue for research purposes. The protocol was approved by the Ethics Committee of Beijing Neurosurgical Institute, Capital Medical University (process no. 201402019).
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- 9.Paxinos G, Watson C. The rat brain in stereotaxic coordinates. 5th ed. San Diego: Elsevier Academic Press; 2005.Google Scholar
- 28.Rizzi M, Perego C, Aliprandi M, Richichi C, Ravizza T, Colella D, Veliskova J, Moshe SL, De Simoni MG, Vezzani A. Glia activation and cytokine increase in rat hippocampus by kainic acid-induced status epilepticus during postnatal development. Neurobiol Dis. 2003;14:494–503.CrossRefPubMedGoogle Scholar
- 29.Tan D, Wu Y, Hu L, He P, Xiong G, Bai Y, Yang K. Long noncoding RNA H19 is up-regulated in esophageal squamous cell carcinoma and promotes cell proliferation and metastasis. Dis Esophagus. 2017;30:1–9.Google Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.